- Home
- CRBP vs DMB Comparison
CRBP vs DMB Comparison
Compare CRBP & DMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBP | DMB |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 194.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CRBP | DMB |
|---|---|---|
| Price | $7.86 | $10.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $50.29 | N/A |
| AVG Volume (30 Days) | ★ 492.2K | 76.6K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.64 | $8.94 |
| 52 Week High | $20.56 | $11.79 |
Technical Indicators
Market Signals| Indicator | CRBP | DMB |
|---|---|---|
| Relative Strength Index (RSI) | 28.92 | 60.52 |
| Support Level | $7.97 | $10.76 |
| Resistance Level | $8.54 | $10.85 |
| Average True Range (ATR) | 0.47 | 0.10 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 5.21 | 72.09 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About DMB BNY Mellon Municipal Bond Infrastructure Fund Inc.
BNY Mellon Municipal Bond Infrastructure Fund, Inc. is a diversified closed-end management investment company. The fund's investment objective is to provide as high a current income exempt from regular federal income tax as is consistent with the preservation of capital. It invests in transportation, energy and utilities, social infrastructure, and water and environmental sectors.